Syntekabio Showcases AI-Driven Drug Discovery Solutions at BioTechX USA

Syntekabio (KOSDAQ: 226330), a leader in artificial intelligence (AI) driven drug development, is set to make a significant impact at the upcoming BioTechX USA conference in Philadelphia, PA, from September 17-18, 2024. As the Title Sponsor for the event, Syntekabio will take center stage to demonstrate its advanced AI-powered solutions that are reshaping the landscape of drug discovery and development.

The company's participation at BioTechX USA comes at a crucial time in the pharmaceutical industry, where the integration of AI technologies is becoming increasingly vital for efficient and cost-effective drug development processes. Syntekabio's presence at the conference underscores the growing importance of AI in addressing complex challenges in drug discovery and optimizing research and development activities.

Dr. Jongsun Jung, CEO of Syntekabio, emphasized the company's eagerness to engage with potential clients at the event. He highlighted Syntekabio's recently announced 'Develop Now, Pay Later' offer, an innovative approach that allows clients to validate target proteins of interest without upfront costs. This model aims to reduce financial barriers in early-stage drug discovery, potentially accelerating the development of new therapeutics.

At BioTechX USA, Syntekabio will showcase its comprehensive suite of AI-driven technologies. The company's DeepMatcher® technology platform, which powers its STB LaunchPad program, is capable of delivering hits, optimized leads, and IND-enabled candidates. Syntekabio's AI infrastructure is impressive, boasting access to over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets that cover more than 70% of human diseases.

The conference will feature two key presentations by Syntekabio executives. Dr. Jonathan Witztum, CTO of Syntekabio USA, will deliver a keynote address on addressing data scarcity in drug discovery using physics-based AI models. Dr. Jongsun Jung will present on flexible molecular docking for neoantigen and antibody drug prediction, highlighting the company's capabilities in personalized medicine and immunotherapy.

Syntekabio will also spotlight its in silico biologics platforms, Neo-ARS™ and Ab-ARS™, which enable the prediction of personalized or universal neoantigen cancer vaccines and novel antibody drugs, respectively. These tools represent significant advancements in the field of computational biology and have the potential to dramatically accelerate the development of targeted therapies and vaccines.

The company's presence at BioTechX USA is supported by its robust AI Bio-Supercom Center, which houses an extensive infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs. This computational power drives Syntekabio's algorithms and enables the rapid processing of vast amounts of biological and chemical data.

For pharmaceutical and biotechnology companies attending BioTechX USA, Syntekabio's booth (#401) will serve as a hub for learning about these innovative AI-driven solutions. Attendees interested in exploring how Syntekabio's technologies can address their pipeline challenges are encouraged to schedule a meeting or visit the booth during the conference.

As the pharmaceutical industry continues to embrace AI technologies, Syntekabio's participation in BioTechX USA represents a significant opportunity for industry professionals to witness firsthand the potential of AI in revolutionizing drug discovery and development. The company's innovative approaches, including the 'Develop Now, Pay Later' model and its advanced AI platforms, position Syntekabio at the forefront of the AI-driven pharmaceutical revolution.

For more information about Syntekabio, STB LaunchPad, and the Develop Now, Pay Later offer, interested parties can click here to learn more about these groundbreaking initiatives in AI-